Vertex Pharmaceuticals Tax Withholding for Share-Based Payments remained flat by 0.0% to $92.48M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 8.7%, from $101.25M to $92.48M. Over 2 years (FY 2023 to FY 2025), Tax Withholding for Share-Based Payments shows an upward trend with a 27.9% CAGR.
An increase often correlates with higher employee stock compensation activity or rising share prices, representing a standard operational cash outflow.
This represents the cash paid by the company to tax authorities on behalf of employees to satisfy tax obligations arisin...
Often disclosed within the 'Financing' section of the cash flow statement as part of share-based payment adjustments.
is_anet_tax_withholding_share_based_payments| FY'23 | FY'24 | FY'25 | |
|---|---|---|---|
| Value | $226.10M | $405.00M | $369.90M |
| YoY Change | — | +79.1% | -8.7% |
We use cookies for analytics. See our Privacy and Cookie Policy.